Nile Therapeutics Announces Poster Presentation at 2009 Heart Failure Society of America Annual Meeting

September 14, 2009

SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ — Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that there will be a poster presented at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.

The abstract presents data from a Phase 1b study of CD-NP in chronic heart failure patients. In this study, a 24-hour infusion of CD-NP resulted in improved renal function as measured by creatinine clearance (p < 0.01) compared with a 24-hour baseline period where patients received standard heart failure medications including furosemide.

“We believe that these data are very promising, and highlight the potential renal benefits of CD-NP compared with existing heart failure medications,” said Joshua Kazam, CEO of Nile Therapeutics. “We look forward to seeing how these results translate to an acute heart failure population in our ongoing Phase II study.”

Abstract #254 will be presented in the CV Pharmacology category. The poster, titled “Initial Observations of Intravenous CD-NP, Chimeric Natriuretic Peptide, on Renal Function in Chronic Heart Failure Patients”, will be presented on Tuesday, September 15th, from 5:30 – 7:00 pm by Steven R. Goldsmith, MD. Dr. Goldsmith is a Professor of Medicine at the University of Minnesota Medical School, the Director of Inpatient Cardiology Services and the Heart Failure Program at Hennepin County Medical Centerk Minneapolis; and is the Director of the Minnesota Heart Failure Consortium

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile’s strategy, future operations, outlook, milestones, the timing and success of Nile’s product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile’s need to raise additional capital to fund its product development programs to completion, Nile’s reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption “Risk Factors” in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission on March 12, 2009 and amended on April 23, 2009. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE Nile Therapeutics, Inc.

Source: newswire

comments powered by Disqus